EpiVax says Novozymes Collaboration has $3bn Potential

EpiVax says Novozymes Collaboration has $3bn Potential by: Gareth Macdonald EpiVax says combining its immune ‘off switch’ drugs with Novozymes’ half-life boosting Albufuse platform could deliver a $3bn (€2.2bn) section of the autoimmune disease market. Full...